Suchergebnisse - "Menter, Alan"

PubPharm (22)

1

Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis : Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2024

von Strober, B. | Bachelez, H. | Crowley, J. | +9

2

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X) : A Randomized Controlled Trial

enthalten in: American journal of clinical dermatology | 2022

von Menter, A. | Cohen, S. | Kay, J. | +9

3

Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis : results from the randomized Phase III VOLTAIRE-PSO study

enthalten in: Expert opinion on biological therapy | 2021

von Menter, A. | Arenberger, P. | Balser, S. | +7

4

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis

enthalten in: The Journal of dermatological treatment | 2020

von Elewski, B. | Menter, A. | Crowley, J. | +7

5

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis : Sub-Group Analysis of the PSO-ABLE Study

enthalten in: American journal of clinical dermatology | 2017

von Paul, C. | Leonardi, C. | Menter, A. | +5

ErratumIn: Am J Clin Dermatol. 2017 May 24;:. - PMID 28540589

6

Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris : Pooled Data From Three Randomized Controlled Studies

enthalten in: Journal of drugs in dermatology : JDD | 2016

von Stein Gold, L. | Lebwohl, M. | Menter, A. | +3

7

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

enthalten in: The New England journal of medicine | 2015

von Lebwohl, M. | Strober, B. | Menter, A. | +32

8

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis : results of the randomized phase 3 CADMUS study

enthalten in: Journal of the American Academy of Dermatology | 2015

von Landells, I. | Marano, C. | Hsu, M. | +10

9

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3) : results from two phase 3 randomised trials

enthalten in: Lancet (London, England) | 2015

von Griffiths, C. | Reich, K. | Lebwohl, M. | +114

CommentIn: Lancet. 2015 Aug 8;386(9993):510-2. - PMID 26072106

10

Secukinumab in plaque psoriasis--results of two phase 3 trials

enthalten in: The New England journal of medicine | 2014

von Langley, R. | Elewski, B. | Lebwohl, M. | +119